Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday, March 12th. Canaccord Genuity Group cut their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $13.97.

Voyager Therapeutics Stock Down 3.9 %

NASDAQ VYGR opened at $2.99 on Tuesday. The firm has a market cap of $165.07 million, a price-to-earnings ratio of 4.21 and a beta of 1.02. The company has a 50-day simple moving average of $3.99 and a two-hundred day simple moving average of $5.41. Voyager Therapeutics has a 12-month low of $2.75 and a 12-month high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the company earned $1.25 earnings per share. Equities analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 15,163 shares of company stock valued at $59,158 over the last three months. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at approximately $29,000. Tower Research Capital LLC TRC grew its stake in shares of Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after buying an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management increased its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after buying an additional 2,444 shares in the last quarter. Oxford Asset Management LLP bought a new stake in Voyager Therapeutics in the fourth quarter worth $60,000. Finally, Tema Etfs LLC bought a new stake in Voyager Therapeutics in the fourth quarter worth $85,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.